Prescribing guide
Fabrazyme (agalsidase beta)Dosing, infusion rate titration, premedication and prior authorization criteria for Fabry diseaseFor prescribers and their offices treating fabry disease: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. Boxed warning: initiate in a healthcare setting with monitoring and CPR equipment. Prior authorization and a site of care before the first infusion.
Example PA threshold
Cigna example: documented low alpha-Gal A activity in leukocytes or fibroblasts, or a pathogenic GLA variant; specialist prescriber; up to 1mg/kg every 2 weeks; no concurrent Galafold or Elfabrio.
Monitoring
Supervised infusion with anaphylaxis readiness at every dose; consider premedication; close monitoring if cardiac function is compromised; consider IgE testing after a severe reaction; no scheduled labs.
Support line
CareConnectPSS Case Managers 1-800-745-4447, option 3 (Monday to Friday 8 AM to 6 PM ET); Co-Pay Program 1-855-448-6520 for eligible commercial plans; Patient Assistance Program for uninsured or denied patients.
Give your patient their plan
A one-page handout for starting Fabrazyme, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/fabrazymeBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in CareConnectPSS | Send the patient a digital consent link, or have them call a Case Manager at 1-800-745-4447 (English option 3, Spanish option 7), Monday to Friday, 8 AM to 6 PM ET, or email info@CareConnectPSS.com. | CareConnect for HCPs |
| Benefits and site of care | CareConnect lists verification of benefits, billing, specialty pharmacy referrals, drug coordination, infusion center identification, home infusion support and travel planning among its services. | CareConnect HCP brochure |
| Ordering and delivery | Purchase through authorized distributors, specialty pharmacies or directly from Sanofi. Rare Disease Product Services, 1-800-745-4447 option 1 or CO@Sanofi.com, sends infusion and refill reminders and has after-hours on-call service. | CareConnect for HCPs |
| Calculate the dose | By actual body weight from 35mg and 5mg single-dose vials (NDC 58468-0040-1, 58468-0041-1). Reconstitute with 7.2mL and 1.1mL sterile water respectively, giving 5mg/mL. Let vials stand about 30 minutes at room temperature first; do not shake. | FDA label |
| Dilute | 0.9% sodium chloride to a total of 50mL (35kg or less), 100mL (35.1 to 70kg), 250mL (70.1 to 100kg) or 500mL (over 100kg); final 0.2 to 0.7mg/mL. Use immediately, or store up to 24 hours at 2°C to 8°C. | FDA label |
| Billing code | HCPCS J0180, injection, agalsidase beta, 1mg, as listed in the Cigna policy. | Cigna policy |
| Co-Pay Program | Commercial only: 100% of eligible out-of-pocket drug costs up to a program maximum, plus specified infusion-related charges. Runs January 1 to December 31; re-enrollment may be needed yearly. Application fax 1-800-750-9839; questions 1-855-448-6520. | Co-Pay Program application |
| Co-Pay exclusions | Excludes Medicare, Part D, Medigap, Medicaid, VA, DoD and TRICARE. Does not cover office visits, nursing observation, blood work, other testing, premedications or transportation. Infusion-related costs not covered for commercial patients in MA or RI. | Fabrazyme support page |
| Patient Assistance Program | Fabrazyme at no cost for eligible patients without insurance or who cannot access it under their plan; described by Sanofi as temporary until coverage is secured. | CareConnect for HCPs |
Prior authorization criteria and what to document
One public policy as the example: Cigna, September 15, 2026. Approval one year, with extended approvals while the patient keeps meeting the criteria and dosing. This policy (Drug Coverage Policy IP0406) cites the July 2024 label, which added the boxed warning. The current DailyMed version from August 2025 changed only wording, so nothing in the policy conflicts with it. The September 2026 update made documentation required for the diagnosis tests. The Blue Cross Blue Shield Federal Employee Program asks only for age 2 or older and Fabry disease, and approves 2 years at a time. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis, enzyme route | Lab test showing deficient alpha-galactosidase A activity in leukocytes or fibroblasts [documentation required] | Enzyme assay report | Cigna policy |
| Diagnosis, genetic route | Molecular genetic test showing a pathogenic variant in GLA [documentation required]; either route qualifies | Genetic test report | Cigna policy |
| Prescriber | Geneticist, endocrinologist, metabolic disorder sub-specialist or lysosomal storage disorder specialist, or in consultation with one | Prescriber specialty or consult note | Cigna policy |
| Dosing | Each dose no more than 1mg/kg IV, no more often than every 2 weeks; other doses reviewed case by case | Order with current weight | Cigna policy |
| Concurrent therapy | Not medically necessary with Galafold (migalastat) or Elfabrio (pegunigalsidase alfa) | Current medication list | Cigna policy |
| Documentation standard | Chart notes, lab tests, claims or receipts; all with patient-specific identifiers (added September 2026) | Labeled copies | Cigna policy |
| Approval | 1 year; extended approvals while criteria and dosing continue to be met (separate reauthorization criteria removed in 2024) | Updated criteria at each review | Cigna policy |
Fabrazyme dosing and titration
| When | Label | Source |
|---|---|---|
| Dose | 1mg/kg actual body weight IV every 2 weeks. | FDA label |
| Before each infusion | Consider pretreatment with antihistamines, antipyretics and/or corticosteroids. | FDA label |
| Starting rate | 0.25mg/min (15mg/hour). | FDA label |
| Titration, 30kg or more | Without hypersensitivity or IARs, increase 0.05 to 0.08mg/min (3 to 5mg/hour) with each subsequent infusion; minimum duration 1.5 hours, based on tolerability. | FDA label |
| Under 30kg | Maximum rate 0.25mg/min (15mg/hour). | FDA label |
| Administration set | In-line low protein binding 0.2 micron filter; do not infuse in the same line with other products. | FDA label |
| Mild or moderate IAR | Consider temporarily holding the infusion, slowing the rate and/or reducing the dose. | FDA label |
| Rechallenge | After a positive skin test or anti-Fabrazyme IgE: 0.5mg/kg at 0.01mg/min (0.6mg/hour), doubling every 30 minutes to 0.25mg/min as tolerated, then increase to 1mg/kg with slow rate titration. | FDA label |
| Pediatric | Indicated from age 2. Established from adult studies, Study 3 (16 patients aged 8 to 16) and data in 24 patients aged 2 to 7. | FDA label |
| Missed dose, renal, hepatic | The label gives no missed-dose instruction and no renal or hepatic impairment section. | FDA label |
Monitoring the Fabrazyme label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each infusion | Hypersensitivity, including anaphylaxis: angioedema, bronchospasm, hypotension, urticaria, dysphagia, rash, dyspnea, flushing, chest discomfort, pruritus, nasal congestion | About 1% anaphylaxis or severe hypersensitivity. If severe, discontinue and treat immediately, including epinephrine; weigh readministration | FDA label |
| Each infusion | Infusion-associated reactions (same day): chills, vomiting, hypotension, paresthesia, pyrexia, dyspnea, nausea, flushing, headache and others | 59% against 27% placebo; severe 5.0% against 1.7%. Severe: discontinue and treat. Most IARs needing intervention eased with a slower rate, a pause, or antipyretics, antihistamines or steroids | FDA label |
| Each infusion | Compromised cardiac function in advanced Fabry disease | Higher risk of severe complications from IARs; monitor closely. Postmarketing: cardiorespiratory arrest, cardiac failure, myocardial infarction | FDA label |
| After a severe reaction | Anti-Fabrazyme IgE | Consider testing and weigh continued treatment; no marketed test, contact Genzyme at 1-800-745-4447 | FDA label |
| First 3 months | Anti-drug antibodies | 83% (110/133) of adults; 77% neutralizing catalytic activity, 6% inhibiting uptake; 69% (11/16) of children. Most seroconvert within 3 months. IARs 76% antibody positive against 30% negative | FDA label |
| Ongoing | Fabry Registry, including pregnancy outcomes | registrynxt.com or 1-800-745-4447, extension 15500; report pregnancy or lactation exposure at 1-800-633-1610, option 1 | FDA label |
Fabrazyme drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Contraindications | None | FDA label |
| Drug interactions | The label has no drug interactions section | FDA label |
| IV line | Do not infuse in the same intravenous line with other products | FDA label |
| Galafold or Elfabrio | Concurrent use not medically necessary under the Cigna policy; the Fabrazyme label does not address it | Cigna policy |
| Pregnancy | Registry sub-study (33 pregnancies with known outcome, 5 exposed in the first trimester), case reports and series: no drug-associated risk identified; no embryo-fetal effects in rats up to 68 times the human dose | FDA label |
| Lactation | Small amounts in human milk; insufficient data on the breastfed infant or milk production | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe Cigna policy below asks for a lab report showing low enzyme activity, or a genetic test showing a disease-causing GLA variant. The genetics clinic's records usually answer what the plan is asking for.
- The prescriber is not a specialistCigna asks that Fabrazyme be prescribed by, or with advice from, a geneticist, endocrinologist, metabolic specialist or lysosomal storage disorder specialist. Prescribing in consultation with one of these specialists also counts.
- Also taking Galafold or ElfabrioCigna treats Fabrazyme given at the same time as Galafold (migalastat) or Elfabrio (pegunigalsidase alfa) as not medically necessary. Your geneticist decides which treatment fits you.
- A copay you cannot payCommercial insurance: the CareConnect Co-Pay Program pays 100% of eligible out-of-pocket drug costs up to a program maximum. Medicare, Medicaid, VA, TRICARE and other government coverage are excluded. Our help paying page lists charity funds that may cover what remains.
- Costs the Co-Pay Program does not coverSanofi lists office visits, nursing observation time, blood work, other tests, medicines given before the infusion and transportation as not covered. Ask your Case Manager about other help.
- You live in Massachusetts or Rhode IslandUnder state law, the Co-Pay Program does not cover infusion-related costs for commercially insured residents of these 2 states. The clinic's infusion charges may then fall on you.
- A new calendar yearThe Co-Pay Program runs from January 1 through December 31. Sanofi says you may need to re-enroll each year to confirm you still qualify.
- No insurance, or the plan will not cover itThe CareConnect Patient Assistance Program may provide Fabrazyme at no cost. Sanofi calls it a temporary solution until coverage can be secured. Call 1-800-745-4447, option 3.
CareConnectPSS (CareConnect Personalized Support Services)
- A Case Manager for insurance, financial help, care coordination and life changes such as travel, moving or new insurance. For Spanish, press 7
- A Patient Education Liaison with a nursing or genetic counseling background, for disease, treatment and inheritance education
- The CareConnect Co-Pay Program for commercial insurance, covering eligible drug costs and certain infusion costs up to a program maximum, with questions answered at 1-855-448-6520
- Co-pay help is not open to Medicare, Medicaid, VA, Department of Defense or TRICARE patients, under the program's terms
- The CareConnect Patient Assistance Program, Fabrazyme at no cost for eligible people without insurance or whose plan will not cover it
- Help finding an infusion center, home infusion support and planning infusions around travel, according to Sanofi's program brochure
Questions prescribers' offices ask about Fabrazyme
What is the Fabrazyme dose for Fabry disease?
1mg/kg actual body weight IV every 2 weeks, per the August 2025 label (text unchanged in substance since July 2024). Start at 0.25mg/min (15mg/hour). In patients 30kg or more without hypersensitivity or IARs, increase by 0.05 to 0.08mg/min (3 to 5mg/hour) with each subsequent infusion, to a minimum duration of 1.5 hours. Under 30kg the maximum rate stays 0.25mg/min.
What does the Fabrazyme boxed warning require?
Initiation in a healthcare setting with appropriate medical monitoring and access to CPR equipment, per the boxed warning added July 2024 and carried in the August 2025 label. Administration should be supervised by a provider knowledgeable in managing anaphylaxis. For severe hypersensitivity, discontinue and treat immediately, including epinephrine. Anaphylaxis has occurred early and after extended therapy.
Should patients be premedicated before Fabrazyme?
Consider antihistamines, antipyretics and/or corticosteroids before each infusion, per the August 2025 label. IARs occurred in 59% on Fabrazyme against 27% on placebo in Studies 1 and 2, where patients were pretreated with antipyretics and antihistamines. IARs may still occur after pretreatment and after extended treatment.
How is a patient rechallenged after a positive IgE or skin test?
0.5mg/kg at 0.01mg/min (0.6mg/hour), doubling the rate every 30 minutes as tolerated to a maximum of 0.25mg/min, per section 2.3 of the August 2025 label. Once tolerated, increase to 1mg/kg and titrate the rate upward slowly. Rechallenge only under direct supervision with support measures available. For IgE testing, contact Genzyme at 1-800-745-4447.
What do insurers ask for to approve Fabrazyme?
The Cigna policy shown here, IP0406 effective September 15, 2026, asks for documented deficient alpha-Gal A activity in leukocytes or fibroblasts or a pathogenic GLA variant, a specialist prescriber, dosing no more than 1mg/kg every 2 weeks, and no concurrent Galafold or Elfabrio. It approves 1 year, with extended approvals while criteria continue to be met.
Free email alert
Get an email when the Fabrazyme label changes
One email the day the FDA revises the Fabrazyme prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Fabrazyme only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- FABRAZYME (agalsidase beta) for injection, for intravenous use, prescribing information (DailyMed SPL version 35), Genzyme Corporation, via DailyMed, 2025-08-22.
- FABRAZYME (agalsidase beta) for injection, for intravenous use, prescribing information, revised 7/2024, FDA, Drugs@FDA, 2024-07-10.
- What Is Fabrazyme® (agalsidase beta) for Fabry Disease?, Sanofi, 2024-07.
- Fabry Disease Resources & Support | Fabrazyme® (agalsidase beta), Sanofi, 2024-07.
- Home | Sanofi CareConnect, Sanofi, 2024-11.
- Our Services and Team | Sanofi CareConnect, Sanofi, 2025-11.
- For Healthcare Professionals, Sanofi, 2024-11.
- Connected Care Throughout the Journey, CareConnect Personalized Support Services (MAT-US-2511683-v1.0-10/2025), Sanofi, 2025-10.
- CareConnect Personalized Support Services Co-Pay Program Application, Enzyme Replacement Therapies (MAT-US-2506611-v1.0-06/2025), Sanofi, 2025-06.
- Enzyme Replacement Therapy – Fabrazyme, Drug Coverage Policy IP0406, Cigna, 2026-09-15.
- Pharmacy Policy 5.30.035, Fabrazyme, Blue Cross Blue Shield Federal Employee Program, 2026-04-01.
- BLA 103979/S-5313 supplement approval letter, boxed warning for hypersensitivity reactions, FDA, 2024-07-10.
- BLA 103979/S-5312 supplement approval letter, hypersensitivity and specific populations labeling, FDA, 2024-02-06.
- BLA 103979/S-5309 supplement approval letter, traditional approval for patients 2 years and older, FDA, 2021-03-11.
A reference drawn from the August 22, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.